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Pathophysiological Role of Hormones and Cytokines in Cancer 
Cachexia
We investigated the role of fasting hormones and pro-inflammatory cytokines in cancer 
patients. Hormones (ghrelin, adiponectin, and leptin) and cytokines (TNF-α, IFN-γ, and   
IL-6) were measured by ELISA or RIA in lung cancer and colorectal cancer patients before 
the administration of cancer therapy, and measurements were repeated every 2 months 
for 6 months. From June 2006 to August 2008, 42 patients (19 with colorectal cancer and 
23 with lung cancer) were enrolled. In total, 21 patients were included in the cachexia 
group and the others served as a comparison group. No significant difference in the initial 
adiponectin, ghrelin, TNF-α, IFN-γ, or IL-6 level was observed between groups, although 
leptin was significantly lower in cachectic patients than in the comparison group 
(15.3 ± 19.5 vs 80.9 ± 99.0 pg/mL, P = 0.007). During the follow-up, the patients who 
showed a  > 5% weight gain had higher ghrelin levels after 6 months. Patients exhibiting 
elevated IL-6 levels typically showed a weight loss > 5% after 6 months. A blunted 
adiponectin or ghrelin response to weight loss may contribute to cancer cachexia and IL-6 
may be responsible for inducing and maintaining cancer cachexia. 
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INTRODUCTION
Anorexia is a condition in which a person has little or no appe-
tite, which results in decreased consumption of food. It is often 
related to a more serious health problem such as cancer, AIDS 
or an emotional disorder. Cachexia is a syndrome characterized 
by weight loss, lipolysis, muscle wasting, anorexia, chronic nau-
sea, and asthenia, with resultant changes in body image. The def-
inition of cachexia varies, but it is generally accepted as a weight 
loss of 5% from pre-illness weight or a weight loss of 25% over 2 
to 6 months (1). Cancer anorexia-cachexia syndrome (CACS) is 
the most common paraneoplastic syndrome and is regarded as 
an indicator of poor prognosis. Half of all cancer patients expe-
rience this syndrome to a mild degree, and it accounts for more 
than 20% of all cancer deaths (2). The mechanism of CACS is 
different from that of starvation; however, it is poorly understood 
and complicated by multiple cancer-associated processes, in-
cluding the secretion of tumor-derived factors, the host inflam-
matory response, changes in cytokine levels, and treatment-in-
duced anorexia. 
  Food intake and energy homeostasis are regulated by a com-
plex network of peripheral mediators, such as hormones, neu-
ropeptides, and cytokines. Ghrelin stimulates food intake and 
ghrelin levels are positively correlated with cachectic states (3-
5). Adiponectin is inversely correlated with body weight (6), and 
leptin acts in the central nervous system (CNS) to suppress food 
intake and stimulate energy expenditure (7, 8). Many host-de-
rived inflammatory mediators that participate in cancer cachex-
ia have been identified; these include tumor necrosis factor-α 
(TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon-γ 
(IFN-γ) (9). However, elevated levels of these cytokines are rare-
ly found in the blood of cancer patients, and regulation by other 
mediators in these patients has not been demonstrated. The re-
lationship between these hormones or cytokines and weight loss 
in cancer patients has not been clearly established. The objec-
tives of our study were to investigate 1) the role of adiponectin, 
leptin, ghrelin, TNF-α, IL-6, and IFN-γ in cancer cachexia, 2) the 
association between hormones and cytokines in cachexia, and 
3) the relationship between the clinical manifestations of cachex-
ia and the levels of adiponectin, leptin, ghrelin, TNF-α, IL-6, and 
IFN-γ in patients with newly diagnosed colon or lung cancer.
MATERIALS AND METHODS 
Subjects 
The study population consisted of newly diagnosed colorectal Kim HJ, et al.  •  Hormones and Cytokines in Cancer Cachexia
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or lung cancer patients from June 2006 to January 2008. The in-
clusion criteria were: 1) pathologically confirmed colorectal or 
lung cancer, 2) age over 18 yr, and 3) a consent form signed and 
dated before the study. Patients who had been treated with che-
motherapy or radiotherapy or had undergone a major opera-
tion within 3 months, had a history of gastrectomy, an eating 
disorder, gastrointestinal obstruction, brain metastasis, second-
ary cancer in another organ, or another primary cachectic state 
(i.e., congestive heart failure, chronic obstructive pulmonary 
disease, or liver cirrhosis) were excluded. The patients were di-
vided into cachexia and non-cachexia groups, with cachexia 
defined as a weight loss of  ≥ 5% from pre-illness weight or over 
6 months.
Hormone and cytokines assays 
Blood samples were collected in the morning after overnight 
fasting for the measurement of adiponectin, ghrelin, leptin, 
TNF-α, IL-6, and IFN-γ, and for complete blood counts and se-
rum chemistry, including lipid profiles. This sampling was not 
permitted when the infection was suspected by the physician. 
Quantikine
® enzyme-linked immunosorbent assay (ELISA) kits 
(R&D Systems, Minneapolis, MN, USA) were used to determine 
the serum levels of adiponectin, leptin, TNF-α, IL-6, and IFN-γ, 
and a radioimmunoassay (RIA) kit (Linco Research, St. Charles, 
MO, USA) was used to determine the serum levels of ghrelin. 
The lower limits of sensitivity for the assays for adiponectin, ghre-
lin, leptin, TNF-α, IL-6, and IFN-γ were 0.246 ng/mL, 93 pg/mL, 
7.8 pg/mL, 1.6 pg/mL, 0.70 pg/mL, and 8.0 pg/mL, respectively. 
All laboratory assays were repeated at 2, 4, and 6 months after 
the initial measurement. 
Statistical analysis 
Continuous variables between the study groups were compared 
using the t-test, the Mann-Whitney U-test, or analysis of vari-
ance (ANOVA), and Pearson’s chi-square or Fisher’s exact test 
was used for categorical variables. Kaplan-Meier analysis with 
a log-rank test was used for survival analysis and to identify fac-
tors affecting survival. All significance tests were two-tailed. 
Ethics statement
The study protocol was approved by the institutional review 
board of Soonchunhyang University Bucheon Hospital (IRB 
No. SCHBC_IRB_06_09). All of the subjected patients submit-
ted informed consent for this study.
RESULTS
Patients’ characteristics 
From June 2006 to January 2008, 42 patients were prospectively 
enrolled. Among these, 16 patients were fully evaluable for 6 
months, whereas 20 patients had expired and six patients were 
transferred to another hospital within the follow-up period. 
Therefore, we analyzed 42 patients at baseline, 28 patients at           
2 months, 24 patients at 4 months, and 16 patients at 6 months. 
The patients’ demographic and clinical characteristics are sum-
marized in Table 1. Of the 42 patients enrolled, 19 patients had 
colorectal cancer (CRC) and the rest were lung cancer patients. 
Half of the patients had cachexia, and the rest of the patients 
(n = 21) were non-cachectic. No significant differences were 
observed in age, type of cancer, rate of metastatic disease, per-
formance status, lipid profile, or the levels of hemoglobin (Hb), 
C-reactive protein (CRP), glucose, insulin, or apoprotein B be-
tween the cachexia and non-cachexia groups. A higher percent-
age of patients in the cachexia group were male than in the non-
cachexia group (90.5 vs 42.8%, P = 0.003), and albumin levels 
were significantly lower within the cachexia group compared to 
the non-cachexia group (3.7 ± 0.5 vs 4.0 ± 0.4 g/dL, respective-
ly; P = 0.041). 
Hormone and cytokine levels at enrollment 
The mean levels of ghrelin and adiponectin were 669.9 ± 299.4 
pg/mL and 98.6 ± 59.4 ng/mL in the cachexia group, and 628.6 ±  
416.0 pg/mL and 88.4 ± 61.4 ng/mL in the non-cachexia group, 
respectively, and no significant difference was observed between 
the two groups. Leptin levels were significantly lower in the ca-
chexia group compared to the non-cachexia group (15.3 ± 19.5 
vs 80.9 ± 99.0 pg/mL, respectively; P = 0.007). The ranges of pro-
inflammatory cytokines varied widely, and the mean levels of 
TNF-α, IFN-γ, and IL-6 were not significantly different between 
the cachexia and non-cachexia groups (Table 2). 
Table 1. Patients’ characteristics 
Parameters
 Cachexia  
 (n = 21)
 Non-cachexia  
 (n = 21)
P value
Age (yr)     62.3 ± 10.1   65.6 ± 9.4 0.277
Disease (CRC: lung cancer)   9:10 10:13 0.757
Metastatic disease (%)     71.4     61.9 0.744
Sex (male:female) 19:2   9:12 0.003
ECOG PS
   0
   1
   2
   3
 
  3
12
  4
  2
 
  4
13
  4
  0
0.400
Albumin (g/dL)     3.7 ± 0.5     4.0 ± 0.4 0.041
Hemoglobin (g/dL)   11.4 ± 1.7   11.5 ± 1.7 0.964
C-reactive protein (mg/dL)     3.0 ± 4.0     1.6 ± 2.3 0.218
Glucose (mg/dL)   104.2 ± 51.0 105.4 ± 7.0 0.868
Insulin (µIU/mL)       8.8 ± 11.6     26.8 ± 44.0 0.789
Apoprotein B (mg/dL)     79.3 ± 22.7     75.3 ± 22.3 0.583
Total cholesterol (mg/dL)   159.7 ± 42.4   167.1 ± 41.9 0.571
LDL cholesterol (mg/dL)   113.2 ± 73.3     95.8 ± 33.2 0.348
HDL cholesterol (mg/dL)     38.4 ± 13.8     47.0 ± 14.5 0.060
TG cholesterol (mg/dL) 104.95 ± 52.0   110.5 ± 85.3 0.804
CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance 
status; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides. 
All continuous variables are represented as means ± standard deviation. Kim HJ, et al.  •  Hormones and Cytokines in Cancer Cachexia
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Differences between patients with CRC and lung cancer 
Clinical characteristics, such as age, rate of metastatic disease, 
sex, albumin, Hb, CRP, and cholesterol levels, did not differ be-
tween CRC and lung cancer patients. In addition, no significant 
difference in the level of ghrelin, adiponectin, leptin, TNF-α, IL-
6, or IFN-γ was observed between patients with CRC and those 
with lung cancer (Table 3).
Analysis of hormone and cytokine levels in relation to 
weight change after 2 months
After 2 months, one patient experienced a weight gain of  > 5%, 
and eight patients experienced weight losses  > 5% compared to 
their state at enrollment. We compared hormone and cytokine 
levels between those who lost weight and those who showed 
no change, excluding the patient who gained weight. Between 
these two groups, no significant difference in ghrelin, adiponec-
tin, leptin, TNF-α, IL-6, or IFN-γ  levels was observed. 
Analysis of hormone and cytokine levels in relation to 
weight change after 4 months 
After 4 months, five patients experienced weight gains > 5%, and 
six patients experienced weight losses > 5% compared to their 
state at enrollment. The levels of ghrelin, adiponectin, and leptin 
at enrollment and 4 months later did not differ between those 
who gained weight, those who lost weight, and those whose 
weight was unchanged. The levels of TNF-α and IFN-γ did not 
differ significantly at baseline or 4 months later between the 
three groups. IL-6 levels showed an increase at 4 months in the 
weight loss group compared to the unchanged and weight gain 
groups, but the difference was not statistically significant (113.6 ±  
Table 2. Hormone and cytokine levels at enrollment 
Hormones/cytokines
Cachexia  
(n = 21)
Non-cachexia  
(n = 21)
P value
Ghrelin (pg/mL) 669.9 ± 299.4 628.6 ± 416.0 0.714
Adiponectin × 100 (ng/mL) 98.6 ± 59.4 88.4 ± 61.4 0.589
Leptin × 100 (pg/mL) 15.3 ± 19.5 80.9 ± 99.0 0.007
TNF-α (pg/mL) 3.1 ± 6.8   77.0 ± 263.9 0.214
IFN-γ (pg/mL)   3.5 ± 10.4 0.6 ± 1.2 0.218
IL-6 (pg/mL) 40.9 ± 67.7   78.7 ± 198.7 0.414
All continuous variables are represented as means ± standard deviation.
Table 3. Differences between patients with CRC and lung cancer 
Parameters
CRC  
(n = 19)
Lung cancer  
(n = 23)
P value 
Age (yr) 62.8 ± 9.5   64.9 ± 10.1 0.512
Metastatic disease (%) 63.1 69.6 0.748
Sex (male:female) 12:7 16:7 0.748
Albumin (g/dL)   3.9 ± 0.5   3.9 ± 0.4 0.905
Hemoglobin (g/dL) 11.2 ± 2.0 11.7 ± 1.4 0.317
C-reactive protein (mg/dL)   2.1 ± 2.9   2.4 ± 3.5 0.774
Total cholesterol (mg/dL) 169.2 ± 48.0 158.7 ± 36.4 0.426
Ghrelin (pg/mL)   651.7 ± 386.5   647.2 ± 342.7 0.968
Adiponectin × 100 (ng/mL)   96.5 ± 58.7   91.0 ± 62.1 0.772
Leptin × 100 (pg/mL)   33.3 ± 48.7   60.4 ± 95.0 0.268
TNF-α (pg/mL)   16.7 ± 60.2     59.3 ± 249.2 0.472
IFN-γ (pg/mL)   2.0 ± 6.7   2.1 ± 8.2 0.945
IL-6 (pg/mL)     57.1 ± 151.3     62.1 ± 148.3 0.914
CRC, colorectal cancer. All continuous variables are represented as means ± standard 
deviation. 
Table 4. Analysis of hormone and cytokine levels in relation to weight change after 4 months
Hormones/Cytokines Weight loss ( > 5%, n = 6) No change (n = 13) Weight gain ( > 5%, n = 5) P value 
Ghrelin (pg/mL)
   Baseline
   4 months
   Change
 
  701.1 ± 440.9
  742.2 ± 455.4
    41.0 ± 556.2
 
  575.3 ± 324.7
179.0 ± 49.6
     -46.1 ± 342.2
 
  759.5 ± 502.2
  851.2 ± 468.3
    43.3 ± 203.9
 
0.627
0.157
0.856
Adiponectin × 100 (ng/mL)
   Baseline
   4 months
   Change
 
  79.5 ± 79.2
126.8 ± 89.1
  47.3 ± 67.2
 
  71.3 ± 48.5
  96.5 ± 53.5
  25.2 ± 59.5
 
  95.3 ± 35.3
110.8 ± 50.2
  18.8 ± 69.2
 
0.717
0.624
0.715
Leptin × 100 (pg/mL)
   Baseline
   4 months
   Change
 
  55.3 ± 67.6
  61.9 ± 92.2
    6.6 ± 50.8
 
    55.1 ± 114.5
  64.1 ± 86.6
    8.9 ± 82.6
 
  81.5 ± 87.4
  177.5 ± 159.5
    21.2 ± 105.5
 
0.872
0.124
0.949
TNF-α (pg/mL)
   Baseline
   4 months
   Change
 
  22.7 ± 44.2
  10.5 ± 16.8
   -12.2 ± 31.2
 
  2.9 ± 8.2
  1.7 ± 2.6
   -1.2 ± 7.1
 
  2.0 ± 2.9
  2.7 ± 4.1
  1.1 ± 2.9
 
0.193
0.137
0.324
IFN-γ (pg/mL)
   Baseline
   4 months
   Change
 
  0.6 ± 1.5
  0.2 ± 0.4
   -0.4 ± 1.7
 
    3.1 ± 10.9
  3.1 ± 9.8
   -0.1 ± 1.6
 
  0.3 ± 0.6
  1.1 ± 2.6
  0.9 ± 2.8
 
0.740
0.722
0.550
IL-6 (pg/mL)
   Baseline
   4 months
   Change  
 
  21.5 ± 35.3
  113.6 ± 261.5
    92.1 ± 271.4
 
  34.4 ± 70.5
  33.2 ± 80.6
     -1.3 ± 18.5
 
  7.2 ± 5.9
  9.4 ± 9.6
  16.0 ± 24.8
 
0.647
0.421
0.720
All continuous variables are represented as means ± standard deviation.Kim HJ, et al.  •  Hormones and Cytokines in Cancer Cachexia
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Table 5. Analysis of hormone and cytokine levels in relation to weight change after 6 months
Hormones/Cytokines Weight loss ( > 5%, n = 3) No change (n = 10) Weight gain ( > 5%, n = 3) P value
Ghrelin (pg/mL)
   Baseline
   6 months
   Change
 
852.7 ± 647.6
654.3 ± 218.1
   -198.5 ± 515.2
 
682.4 ± 388.2
594.2 ± 218.1
   -88.2 ± 463.9
 
1040.0 ± 365.3
1223.1 ± 383.7
  183.2 ± 397.4
 
0.458
0.007
0.581
Adiponectin × 100 (ng/mL)
   Baseline
   6 months
   Change
 
  99.0 ± 112.3
91.5 ± 72.6
   -7.5 ± 51.0
 
58.9 ± 33.1
79.0 ± 54.4
20.1 ± 36.5
 
  95.6 ± 38.2
  166.9 ± 131.6
    71.3 ± 112.1
 
0.413
0.235
0.357
Leptin × 100 (pg/mL)
   Baseline
   6 months
   Change
 
52.1 ± 73.0
41.4 ± 56.9
   -10.7 ± 16.5
 
  81.8 ± 134.9
34.3 ± 32.1
   -47.5 ± 134.2
 
  81.5 ± 92.9
  96.4 ± 48.1
  14.8 ± 49.1
 
0.931
0.092
0.682
TNF-α (pg/mL)
   Baseline
   6 months
   Change
 
  7.9 ± 11.8
17.1 ± 24.1
  9.2 ± 32.3
 
12.3 ± 34.8
  40.2 ± 107.9
  27.9 ± 116.9
 
  1.2 ± 2.1
10.0 ± 8.9
    8.7 ± 11.0
 
0.847
0.847
0.933
IFN-γ (pg/mL)
   Baseline
   6 months
   Change
 
1.2 ± 2.1
0.0 ± 0.0
   -1.2 ± 2.1
 
  4.0 ± 12.5
11.7 ± 35.5
  7.6 ± 23.1
 
  0.0 ± 0.0
  0.2 ± 0.4
  0.2 ± 0.4
 
0.810
0.756
0.718
IL-6 (pg/mL)
   Baseline
   6 months
   Change
 
44.6 ± 44.7
217.2 ± 372.6
172.6 ± 407.1
 
12.1 ± 10.8
  56.7 ± 143.9
  44.7 ± 143.8
 
  4.1 ± 4.9
  32.2 ± 38.4
  28.1 ± 41.7
 
0.048
0.410
0.598
All continuous variables are represented as means ± standard deviation.
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OS (weeks)
Ghrelin
0.0  25.0  50.0  75.0  100.0  125.0
1.0
0.8
0.6
0.4
0.2
0.0
P = 0.159
< 649.2
≥ 649.2 
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l
OS (weeks)
Adiponectin
0.0  25.0  50.0  75.0  100.0  125.0
1.0
0.8
0.6
0.4
0.2
0.0
P = 0.455
< 93.5
≥ 93.5
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v
i
v
a
l
OS (weeks)
Leptin
0.0  25.0  50.0  75.0  100.0  125.0
1.0
0.8
0.6
0.4
0.2
0.0
P = 0.285
< 48.1
≥ 48.1
Fig. 1. Prognostic factors for survival.
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TNF-α
0.0  25.0  50.0  75.0  100.0  125.0
1.0
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P = 0.155
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IFN-γ
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P = 0.803
< 2.04
≥ 2.04
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IL-6
0.0  25.0  50.0  75.0  100.0  125.0
1.0
0.8
0.6
0.4
0.2
0.0
P = 0.442
< 12.6
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261.5 vs 33.2 ± 80.6 vs 9.4 ± 9.6 pg/mL, respectively; P = 0.421; 
Table 4).
Analysis of hormone and cytokine levels in relation to 
weight change after 6 months 
After 6 months, three patients experienced weight gains > 5%, 
and three patients experienced weight losses > 5%, compared 
to their state at enrollment. We found that ghrelin levels were 
significantly higher in patients showing weight gain compared 
to the unchanged and weight loss groups (1,223.1 ± 383.7 vs 
594.2 ± 218.1 vs 654.3 ± 218.1 pg/mL, respectively; P = 0.007). 
No significant difference was detected in the levels of adiponec-
tin, leptin, TNF-α, or IFN-γ at enrollment or 6 months later or 
from the time of enrollment to 6 months later among the three 
weight groups. The baseline IL-6 level was higher in the weight 
loss group than in the unchanged or weight gain group (44.6 ±  
44.7 vs 12.1 ± 10.8 vs 4.1 ± 4.9 pg/mL, respectively; P = 0.048). 
After 6 months, the level of IL-6 showed an overall increase in 
the weight loss group compared to the unchanged and weight 
gain groups, but the difference was not statistically significant 
(217.2 ± 372.6 vs 56.7 ± 143.9 vs 32.2 ± 38.4 pg/mL, respective-
ly; P = 0.410; Table 5). 
Prognostic factors for survival 
No significant prognostic factor for survival was identified 
through our Kaplan-Meier survival analysis of ghrelin, adipo-
nectin, leptin, TNF-α, IFN-γ, and IL-6 levels (Fig. 1). 
DISCUSSION 
CACS is associated with poor prognosis, including an increased 
risk of postoperative complications, impaired immune and pul-
monary function, impaired tolerance to anti-neoplastic treat-
ment, decreased quality of life, and shortened survival. Although 
the incidence of cancer cachexia varies among cancer types, 
50% of all cancer patients experience this syndrome to a mild 
degree and 15% experience a loss of greater than 10% of base-
line body weight. At the time of diagnosis, 80% of patients with 
upper gastrointestinal cancer and 60% of patients with lung can-
cer already demonstrate substantial weight loss (10). In addi-
tion, cancer treatment and medication for concurrent condi-
tions may contribute to cancer cachexia. Cancer cachexia dif-
fers from malnutrition in starvation (11). The most common 
form of nutritional depletion in cancer cachexia is protein-cal-
orie malnutrition, resulting in the loss of cell mass without de-
pletion of vitamins or trace minerals (11). The existence of me-
diators in cancer cachexia that differ from those observed in 
starvation has been recognized. For example, the ventromedial 
hypothalamus (VMH), the serotonergic system, TNF-α, IL-6, 
IFN-γ, neuropeptide Y, nitric oxide, and leptin have been iden-
tified as central mediators of cachexia in animal studies (9). How-
ever, the mechanisms of cancer cachexia are not well defined, 
and no consensus has been reached regarding the role of me-
diators such as cytokines in cancer cachexia until now. Togeth-
er with cytokines, hormones have a significant role in food in-
take and energy homeostasis; however, the pathophysiological 
role of these hormones has not been fully elucidated in cancer 
cachexia. 
  Ghrelin has growth hormone-releasing activity, stimulates 
food intake, induces adiposity, and inhibits leptin-induced re-
duction in feeding. In previous reports, ghrelin levels were posi-
tively correlated with decreased body mass index, and were 
higher in lung cancer patients than in healthy individuals (12). 
However, in the present study, no significant difference in ghre-
lin levels was observed between the cachexia and non-cachexia 
groups at baseline, although patients with weight gain at later 
time points showed significantly higher ghrelin levels than other 
groups. These results may indicate an impaired ghrelin response 
in cancer patients with cachexia. However, ghrelin may have 
potential as a treatment for cancer cachexia. Studies in a rat mod-
el demonstrated positive effects after ghrelin treatment, which 
may have involved orexigenic neuropeptides and anti-inflam-
matory (13). Thus, a clinical trial involving the administration of 
ghrelin in human cancer cachexia may be warranted. 
  Adiponectin levels are inversely correlated with body weight, 
and therefore low adiponectin levels are typically observed in 
obese individuals (14). However, low adiponectin levels have 
been reported in individuals who experienced weight loss with 
advanced lung cancer (15). We did not observe an inverse cor-
relation between body weight change and adiponectin levels; 
adiponectin levels did not differ significantly between the ca-
chexia and non-cachexia groups. We observed no significant 
difference or change in adiponectin levels with weight change 
during follow-up. Thus, the impaired regulation of adiponectin 
with weight change may contribute to cancer cachexia, and fur-
ther study is required to determine the pathophysiological role 
of adiponectin in cancer cachexia. 
  Leptin is known to act in the CNS to suppress food intake and 
stimulate energy expenditure; however, no consistent relation-
ship has been demonstrated between leptin and cancer cachex-
ia. Existing data on the association between leptin levels and 
cancer are contradictory. Leptin levels were reportedly low in 
gastrointestinal cancer patients, but high in those with breast 
cancer (16-18). In our study, leptin was significantly suppressed 
in the cachexia group compared to the non-cachexia group; 
therefore, we suggest that leptin may be regulated normally in 
cancer cachexia, unlike adiponectin and ghrelin. We also found 
no significant difference in leptin levels between patients with 
CRC and those with lung cancer. Leptin and adiponectin were 
reported to be down-regulated by TNF-α in cachexia (19, 20), 
and ghrelin suppresses production of cytokines such as IL-6 
and TNF-α (21, 22), but we did not find any reverse correlation Kim HJ, et al.  •  Hormones and Cytokines in Cancer Cachexia
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between TNF-α and leptin or ghrelin. We found no significant 
difference in cytokines between the cachexia and non-cachexia 
groups at baseline measurement; however, the wide range of 
values observed may have resulted in statistical bias. Important-
ly, our results indicated that high IL-6 levels at baseline were 
maintained and increased in patients who later experienced 
weight loss. We suggest that IL-6 may be responsible for induc-
ing and maintaining cancer cachexia. These results are support-
ed by the finding of Baltgalvis et al. (23) that IL-6 overexpression 
in Apc
Min/+/IL-6
-/- mice led to a decrease in muscle and fat mass 
and increased the intestinal polyp burden. 
  We also used Kaplan-Meier analysis to investigate the role of 
hormones and cytokines as predictive and prognostic markers. 
According to this analysis, ghrelin, adiponectin, leptin, TNF-α, 
IFN-γ, and IL-6 levels are not significant predictive factors of 
survival. However, patients with high ghrelin, low adiponectin, 
high leptin, high TNF-α, or low IL-6 had a tendency toward pro-
longed survival, although it did not cross the threshold for statis-
tical significance in the survival curve. Therefore, further stud-
ies are needed to determine the roles of these hormones and 
cytokines as prognostic markers. 
  The limitations of this study include a small number of pa-
tients, which may have resulted in statistical errors, particularly 
in the follow-up testing. Nevertheless, the results of this prospec-
tive study may contribute to the understanding of the patho-
genesis and treatment of cancer cachexia. 
  In summary, we found that 1) leptin levels decreased signifi-
cantly in patients with cachexia compared to those without, but 
ghrelin and adiponectin levels were not significantly altered; 2) 
ghrelin levels were significantly higher in patients with weight 
gain, but leptin and adiponectin did not change significantly 
with weight change; 3) patients who experienced weight loss 
showed increased IL-6 levels at baseline and throughout the 
follow-up compared to the weight gain and no change groups; 
and 4) no significant prognostic factor for survival was identi-
fied among the hormones and cytokines examined. 
  In conclusion, these results suggest that impaired responsive-
ness of adiponectin and ghrelin may contribute to cancer ca-
chexia and that IL-6 may be responsible for inducing and main-
taining cancer cachexia. Furthermore, our data suggest that a 
clinical trial for the administration of ghrelin in cancer cachexia 
treatment may be warranted. 
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